Amifostine: Is There Evidence of Tumor Protection?

Seminars in Oncology

Volumn 30, Issue 6 SUPPL. 18, 2003, Pages 18-30

  Koukourakis, Michael I ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Tumor and Angiogenesis Research Group Alexandroupolis   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALKYLATING AGENT; AMIFOSTINE; ANESTHETIC AGENT; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIMETHYL SULFOXIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MAFOSFAMIDE; MELPHALAN; MERCAPTAMINE; PACLITAXEL; PLATINUM; TETRAPLATIN; THIOPENTAL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACTIVITY; DRUG MEGADOSE; HUMAN; HYPOTENSION; HYPOXIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CANCER; OXYGEN TISSUE LEVEL; PRIORITY JOURNAL; PROTECTION; QUALITY OF LIFE; RADIATION SICKNESS; RADIOSENSITIVITY; SKIN PROTECTION; SURVIVAL RATE; TISSUE NECROSIS;

EID: 1642558247     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.11.014     Document Type: Conference Paper

References (84)

1. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
2. Brizel DM, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345, 2000
3. Yuhas JM, Storer JB: Differential cytoprotection of normal and malignant tissues. J Natl Cancer Inst 42:331-335, 1969
4. Yuhas JM: Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 63:971-976, 1979
5. Yuhas JM, Culo F: Selective inhibition of nephrotoxicity of cis-platinum without altering its antitumor effectiveness. Cancer Treat Rep 64:57-64, 1980
6. Yuhas JM, Spellman JM, Jordan SW, et al: Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42: 574-585, 1980
7. Valeriote F, Grates HE: Dose and interval relationship for the interaction of WR-2721 and mustard with normal and malignant cells. Int J Radiat Oncol Biol Phys 10:1561-1564, 1984
8. Clement JJ, Johnson RK: Influence of WR 2721 on the efficacy of radiotherapy and chemotherapy of murine tumors. Int J Radiat Oncol Biol Phys 8:539-542, 1982
9. Mendiondo OA, Grigsby PW, Beach JL: Radioprotection combined with hypoxic sensitization during radiotherapy of a solid murine tumor. Radiology 148:291-293, 1983
10. Penhaligon M: Radioprotection of mouse skin vasculature and the RIF-1 fibrosarcoma by WR-2721. Int J Radiat Oncol Biol Phys 10:1541-1544, 1984
11. Milas L, McBride WH, Hunter N, et al: Protection by S-2-(3-aminopropylamino) ethylphosphorothioic acid against radiation and cyclophosphamide-induced attenuation in anti-tumor resistance. Cancer Res 44:2382-2386, 1984
12. Wist EA: Effect of the radioprotector WR 2721 on the response of metastatic Lewis lung carcinoma colonies to alkylating agents. Acta Radiol Oncol 24:259-262, 1985
13. 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR-77913). Radiat Res 102:130-137, 1985
14. DeNeve WJ, Everett CK, Suminski JE, et al: Influence of WR-2721 on DNA-cross linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 48:6002-6005, 1988
15. Besa PC, Hunter NR, Milas L: Improvement in radiotherapy for a murine sarcoma by indomethacin plus WR-2721. Radiat Res 135:93-97, 1993
16. Treskes M, Boven E, van de Loosdrecht AA, et al: Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30A:183-187, 1994
17. Paine GD, Taylor CW, Lopez MH, et al: Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: Preliminary results. Semin Oncol 23:35-39, 1996 (suppl 8)
18. Dunn TA, Schmoll HJ, Gruml V, et al: Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs 7:795-799, 1996
19. Fichtner I, Lemm M, Becker M, et al: Effects of amifostine (WR-2721, Ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas. Anticancer Drugs 8:174-181, 1997
20. Bergstrom P, Johnson A, Bergenheim T, et al: Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. J Neurooncol 42:13-21, 1999
21. Grdina DJ, Hunter N, Kataoka Y, et al: Chemopreventive doses of amifostine confer no cytoprotection in tumor nodules growing in the lungs of mice treated with cyclophosphamide. Semin Oncol 26:22-27, 1999 (suppl)
22. Symon Z, Levi M, Ensminger WD, et al: Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model. Int J Radiat Oncol Biol Phys 50:473-478, 2001
23. Treskes M, Nijtmans L, Fichtinger, Schepman AM, et al: Cytostatic activity of cisplatin in the presence of WR2721 aminothiol metabolite WR1065 in OVCAR-3 human ovarian cancer as compared to V79 fibroblasts. Anticancer Res 12: 2261-2265, 1992
24. Douay L, Hu C, Giarratana MC, et al: Amifostine improves the antileukemic therapeutic index of mafosfamide: Implications for bone marrow purging. Blood 86:2849-2855, 1995
25. Douay L, Hu C, Giarratana MC, et al: Amifostine (WR-2721) protects normal haematopoietic stem cells against cyclophosphamide derivatives' toxicity without compromising their antileukaemic effects. Eur J Cancer 31A:S14-S16, 1995 (suppl 1)
26. Alberts DS, Speicher LA, Krutzsch M, et al: WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Eur J Cancer 32:17-20, 1996 (suppl 4)
27. Taylor CW, Wang LM, List AF, et al: Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer 33:1693-1698, 1997
28. Ng Y, Ngan HTS, Cheng DKL, et al: The effects of amifostine on the in vitro cytotoxicity of chemotherapeutic agents in three epithelial ovarian carcinoma cell lines. Gynecol Oncol 75:194-197, 1999
29. Renner S, Krumpelman S, Bruchelt G, et al: Effect of amifostine on neuroblastoma during high dose chemotherapy: In vivo and in vitro investigations. Anticancer Res 20:4531-4538, 2000
30. Shen H, Chen ZJ, Zilfou JT, et al: Binding of the aminothiol WR-1065 to transcriptional factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther 297: 1067-1073, 2001
31. Shaw LM, Bonner HS, Turssi A, et al: A liquid chromatographic electrochemical assay for S-2-(3-aminopropylamino)ethylphosphorythiate (WR-2721) in human plasma. J Liq Chromatogr 7:2447-2465, 1984
32. Giatromanolaki A, Sivridis E, Maltezos E, et al: Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. Semin Oncol 29:14-21, 2002 (suppl 19)
33. Lowy RO, Baker DG: Protection against local irradiation injury to the skin by locally and systemically applied drugs. Radiology 105:425-428, 1972
34. Moulder JE, Lo PS, Fischer JJ: Effect of the radioprotective drugs MEA, DMSO, and WR-2721 on tumor control and skin tolerance in the rat. Cancer Treat Rep 61:825-833, 1977
35. Twentyman PR: Modification by WR-2721 of the response to chemotherapy of tumours and normal tissues in the mouse. Br J Cancer 47:57-63, 1983
36. Milas L, Hunter N, Reid BO, et al: Protective effects of S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation damage of normal tissues and a fibrosarcoma in mice. Cancer Res 42:1888-1897, 1982
37. Stewart FA, Rojas A, Denakamp J: Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments. Int J Radiat Oncol Biol Phys 9:507-513, 1983
38. Milas L, Hunter N, Ito H, et al: Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721. Int J Radiat Oncol Biol Phys 10:41-48, 1984
39. Rojas A, Stewart FA, Soranson JA, et al: Fractionation studies with WR-2721: Normal tissues and tumour. Radiother Oncol 6:51-60, 1986
40. McChesney SL, Gillette EL, Dewhirst MW, et al: Influence of WR-2721 on radiation response of canine soft tissue sarcomas. Int J Radiat Oncol Biol Phys 12:1957-1963, 1986
41. Blasiak J, Gloc E, Mlynarski W, et al: Amifostine differentially modulates DNA damage evoked by idarubicin in normal and leukemic cells. Leuk Res 26:1093-1096, 2002
42. Twentyman PR, Brown JM, Gray JW, et al: A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 64:595-604, 1980
43. Kim JH, Alfieri AA, Kim SH, et al: Radiosensitization of two murine fibrosarcomas with 6-thioguanine. Int J Radiat Oncol Biol Phys 10:41-48, 1990
44. Kataoka Y, Perrin J, Hunter N, et al: Antimutagenic effects of amifostine: Clinical implications. Semin Oncol 23: 53-57, 1996 (suppl 8)
45. Koukourakis MI, Ktenidou-Kartali S, Bourikas G, et al: Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunol Immunother 52: 127-131, 2003
46. Cairns RA, Kalliomaki T, Hill RP: Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 61:8903-8908, 2001
47. Crowe NY, Smyth MJ, Godfrey DI: A critical role of natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196:119-127, 2002
48. Sawiki B, Kasacka I, Chyczewski L: Preliminary evaluation of mast cells and angiogenesis process in fibrosarcoma. Folia Histochem Cytobiol 40:197-198, 2002
49. Ichinose Y, Yasumoto K, Tanaka K, et al: Combined treatment of autochthonous 3-methylcholanthrene-induced murine tumors by immunotherapy and radiotherapy. Gann 74:143-147, 1983
50. Nelson M, Nelson DS, Hopper KE: Tumor growth in mice with depressed capacity to mount inflammatory responses: Possible role of macrophages. Am J Pathol 104:114-124, 1981
51. Zuckerberg AL, Goldberg LI, Lederman HM: Effects of hypoxia on interleukin-2 mRNA expression by T lymphocytes. Crit Care Med 22:197-203, 1994
52. Gelfand JA: Too little oxygen, too little interleukin-2: A link between hypoxemia and cellular immune dysfunction. Crit Care Med 22:187-188, 1994
53. Leek RD, Harris AL: Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7:177-189, 2002
54. Denekamp J, Michael BD, Rojas A, et al: Radioprotection of mouse skin by WR-2721: The critical influence of oxygen tension. Int J Radiat Oncol Biol Phys 8:531-534, 1982
55. Rojas A, Denekamp J: The influence of X ray dose levels on normal tissue radioprotection by WR-2721. Int J Radiat Oncol Biol Phys 10:2351-2356, 1984
56. Rojas A, Stewart FA, Denekamp J: Interaction of misonidazole and WR-2721-II. Modification of tumour radiosensitization. Br J Cancer 47:65-72, 1983
57. Utley JF, Phillips TL, Kane LJ, et al: Differential radioprotection of euoxic and hypoxic mouse mammary tumors by a thiophosphate compound. Radiology 110:213-216, 1974
58. Lindegaard JC, Grau C: Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 57: 113-118, 2000
59. Andreassen CN, Grau C, Lindegaard JC: Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 13:62-72, 2003
60. Maciejewski B, Taylor JM, Wither HR: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7:323-326, 1986
61. Thompson C, Wyrick SD, Holbrook DJ, et al: Effects of the cytoprotective agent WR-2721 on disposition and biotransformation of ormaplatin in the Fisher 344 rat bearing fibrosarcoma. Cancer Res 55:2837-2846, 1995
62. Planting AS, Catimel G, de Mulder PH, et al: Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer: EORTC Head and Neck Cooperative Group. Ann Oncol 10:693-700, 1999
63. Johnson PWM, Muers MF, Peake MD, et al: A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer. Br J Cancer 84:19-24, 2001
64. Gelmon K, Eisenhauer E, Bryce C, et al: Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17:3038-3047, 1999
65. Budd GT, Ganapathi R, Adelstein DJ, et al: Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 80:1134-1140, 1997
66. Rick O, Beyer J, Schwella N, et al: Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann Oncol 12:1151-1155, 2001
67. Liu T, Liu Y, He S, et al: Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 69:2820-2825, 1992
68. Kligerman MM, Liu Y, Scheffler B, et al: Interim analysis of a randomized trial of radiation therapy of rectal cancer with/without WR-2721. Int J Radiat Oncol Biol Phys 22:799-802, 1992
69. Buntzel J, Kuttnet K, Frohlich D, et al: Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9:505-509, 1998
70. Buntzel J, Schuth J, Kuttner K, et al: Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6:155-160, 1998
71. Peters K, Mucker R, Hamann D, et al: Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy: Is it possible to limit the duration of the application of amifostine? Strahlenther Onkol 175:23-26, 1999 (suppl 4)
72. Antonadou D, Pepelassi M, Synodinou M, et al: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747, 2002
73. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
74. Antonadou D: Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Semin Oncol 12:50-58, 2002 (suppl 1)
75. Antonadou D, Coliarakis N, Synodinou M, et al: A randomized phase III trial of radiation treatment ± amifostine in patients with advanced stage lung cancer. Int J Radiat Oncol Biol Phys 51:915-922, 2001
76. Komaki R, Lee JS, Kaplan B, et al: Randomized phase III study of chemoradiation ± amifostine in patients with inoperable stage II-III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:325a, 2001 (abstr 1298)
77. Koukourakis MI, Romanidis K, Froudarakis M, et al: Concurrent administration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: Excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87:385-392, 2002
78. Koukourakis MI, Giatromanolaki A, Kouroussis C, et al: Tumor and Angiogenesis Research Group. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): A short, safe, and effective postoperative regimen for high-risk breast cancer patients. Int J Radiat Oncol Biol Phys 52:144-155, 2002
79. Koukourakis MI, Giatromanolaki A, Galazios G, et al: Molecular analysis of local relapse in high-risk breast cancer patients: Can radiotherapy fractionation and time factors make a difference? Br J Cancer 88:711-717, 2003
80. Koukourakis MI, Giatromanolaki A, Kakolyris S, et al: Phase I/II close escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemoradiotherapy: Additional chemotherapy enhances regression of residual cancer. Med Oncol 17:135-143, 2000
81. Provinciali M, Ciavattini A, Di Stefano G, et al: In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci 64:1525-1532, 1999
82. Harris JW, Meneses JJ: Radioprotection of immunologically reactive T lymphocytes by WR-2721. Int J Radiat Oncol Biol Phys 4:437-440, 1978
83. Grdina DJ, Kataoka Y, Murley JS, et al: Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice. Semin Oncol 29:22-28, 2002 (suppl 19)
84. Grdina DJ, Kataoka Y, Murley JS, et al: Inhibition of spontaneous metastases formation by amifostine. Int J Cancer 97:135-141, 2002